Department of Bioscience and Biotechnology, Sejong University, Seoul, Republic of Korea.
Life Sci. 2012 Feb 27;90(9-10):373-80. doi: 10.1016/j.lfs.2011.12.010. Epub 2011 Dec 28.
We investigated whether cAMP-mediated protein kinase A(PKA) and Epac1/Rap1 pathways differentially affect brain tumor cell death using 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone(rolipram), specific phosphodiesterase type IV(PDE IV) inhibitor.
A172 and U87MG human glioblastoma cells were used. Percentage of cell survival was determined by MTT assay. PKA and Epac1/Rap1 activation was determined by western blotting and pull-down assay, respectively. Cell cycle and hypodiploid cell formation were assessed by flow cytometry analysis.
Non-specific PDE inhibitors, isobutylmethylxanthine(IBMX) and theophylline reduce survival percentage of A172 and U87MG cells. The expression of PDE4A and PDE4B was detected in A172 and U87MG cells. Rolipram-treated A172 or U87MG cell survival was lower in the presence of forskolin, adenylate cyclase activator, than that in its absence. Co-treatment with rolipram and forskolin also enhanced CREB phosphorylation on serine 133 that was inhibited by H-89, PKA inhibitor and cAMP-responsive guanine nucleotide exchange factor 1(Epac1), a Rap GDP exchange factor-mediated Rap1 activity in A172 cells. When A172 cells were treated with cell-permeable dibutyryl-cAMP(dbcAMP), PKA activator or 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate(CPT), Epac1 activator, basal level of cell death was increased and cell cycle was arrested at the phase of G2/M. Rolipram-induced A172 cell death was also increased by the co-treatment with dbcAMP or CPT, but it was inhibited by the pre-treatment with H-89.
These findings demonstrate that PKA and Epac1/Rap1 pathways could cooperatively play a role in rolipram-induced brain tumor cell death. It suggests that rolipram might regulate glioblastoma cell density through dual pathways of PKA- and Epac1/Rap1-mediated cell death and cell cycle arrest.
我们使用 4-(3-环戊氧基-4-甲氧基苯基)-2-吡咯烷酮(rolipram),一种特异性磷酸二酯酶 4(PDE4)抑制剂,研究 cAMP 介导的蛋白激酶 A(PKA)和 Epac1/Rap1 通路是否对脑肿瘤细胞死亡有不同影响。
采用 A172 和 U87MG 人神经胶质瘤细胞。通过 MTT 测定法确定细胞存活率。通过 Western blot 和下拉测定法分别测定 PKA 和 Epac1/Rap1 的激活情况。通过流式细胞术分析评估细胞周期和亚二倍体细胞形成。
非特异性 PDE 抑制剂异丁基甲基黄嘌呤(IBMX)和茶碱降低 A172 和 U87MG 细胞的存活率。A172 和 U87MG 细胞中检测到 PDE4A 和 PDE4B 的表达。与无福司可林(一种腺苷酸环化酶激活剂)相比,福司可林处理的 A172 或 U87MG 细胞的存活率较低。用 rolipram 和福司可林共同处理也增强了 A172 细胞中 CREB 丝氨酸 133 的磷酸化,而这种磷酸化被 PKA 抑制剂 H-89 和 cAMP 反应性鸟嘌呤核苷酸交换因子 1(Epac1)抑制,Epac1 是 Rap GDP 交换因子介导的 Rap1 活性。当 A172 细胞用细胞通透性二丁酰环磷酸腺苷(dbcAMP),PKA 激活剂或 8-(4-氯苯硫基)-2'-O-甲基腺苷-3',5'-环单磷酸(CPT),Epac1 激活剂处理时,细胞死亡的基础水平增加,细胞周期停滞在 G2/M 期。用 dbcAMP 或 CPT 共同处理也增加了 rolipram 诱导的 A172 细胞死亡,但用 H-89 预处理可抑制这种作用。
这些发现表明,PKA 和 Epac1/Rap1 通路可以协同作用于 rolipram 诱导的脑肿瘤细胞死亡。这表明 rolipram 可能通过 PKA-和 Epac1/Rap1 介导的细胞死亡和细胞周期阻滞的双重途径调节神经胶质瘤细胞密度。